Cognitive dysfunction and dementia in Parkinson disease
Nuria Caballol1, Maria J Martí, Eduardo Tolosa
1Parkinson's Disease and Movement Disorders Unit, Neurology Service, Institut Clínic de Neurociencies, Institut d'Investigacions Biomèdiques August Pi i Sunyer, Hospital Clínic Universitari, University of Barcelona, Barcelona, Spain.
Summary
Cognitive impairment is common in Parkinson disease (PD), with a higher risk for developing Parkinson disease dementia (PDD). Cholinesterase inhibitors show promise for treating PDD and associated behavioral symptoms.
Area of Science:
- Neurology
- Neuroscience
- Cognitive Science
Background:
- Cognitive impairments, including executive functions, memory, and visuospatial skills, are prevalent in Parkinson disease (PD), even early on.
- Parkinson disease dementia (PDD) risk is elevated (2-6x general population) and correlates with disease duration.
- PD dementia presents with insidious onset, slow cognitive decline, dysexecutive syndrome, and behavioral symptoms like hallucinations and depression.
Purpose of the Study:
- To review the cognitive and behavioral manifestations of Parkinson disease dementia (PDD).
- To explore the potential pathophysiology and neurobiological underpinnings of PDD.
- To evaluate current and emerging therapeutic strategies for PDD.
Main Methods:
- Literature review of studies on cognitive impairment in Parkinson disease.
- Analysis of clinical characteristics and progression of Parkinson disease dementia.
- Examination of neurobiological hypotheses including Lewy-body pathology, Alzheimer-like changes, and neurotransmitter dysfunction.
Main Results:
- Cognitive decline is a frequent complication of PD, increasing with disease duration.
- PDD is characterized by dysexecutive syndrome and behavioral disturbances.
- Cholinergic deficit is a key mechanism in PDD development, alongside Lewy-type and Alzheimer-like pathology.
Conclusions:
- Cognitive impairment and dementia are significant challenges in Parkinson disease management.
- Understanding the neurobiological basis of PDD is crucial for developing effective treatments.
- Cholinesterase inhibitors represent a promising therapeutic avenue for PDD and its associated behavioral symptoms.
Related Concept Videos
01:24Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
01:15Parkinson's Disease: Overview
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
01:24Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
01:24Parkinson Disease l: Introduction
Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
01:30Dementia
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual.
The progression of dementia is generally gradual.